Funding
Funding not disclosed
Founders
Product
Problem
Veterinary parasitic diseases, such as fasciolosis in livestock and heartworm in companion animals, cause significant economic losses and pose a continuous threat to animal health. Current control methods often rely on chemical treatments that can lead to resistance and residue issues.
Solution
FABP Biotech develops anti-helminth vaccines for animal use, leveraging proprietary Sm14 recombinant protein technology. This platform targets major veterinary parasitic infections by stimulating the host immune system to produce antibodies that neutralize parasite functions. The company's approach offers a safe, effective, and environmentally friendly alternative to traditional anthelmintic treatments. FABP Biotech focuses on strategic business partnerships to navigate regulatory approval processes and bring these innovative biotechnological solutions to the global market.
Target Audience
The primary target audience includes veterinary pharmaceutical companies, livestock producers, and pet care product distributors seeking advanced solutions for parasitic disease control.
Features
- Sm14 recombinant protein technology for anti-helminth vaccine development.
- LIVAC® vaccine candidate targeting fasciolosis in livestock (cattle, goats, sheep).
- Sm14PET vaccine candidate targeting heartworm disease in companion animals (dogs).
- Mechanism of action involves inducing host antibodies against parasite fatty acid binding proteins (FABPs) to disrupt lipid transport and immune modulation.
- Focus on developing vaccines that are safe, effective, and environmentally sustainable.
- Business model centered on strategic alliances and licensing deals for global market access.